Consensus Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
9.67 ^USD	+0.94%		+2.65%	-43.28%

May. 14	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT
May. 14	Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	CI

Evolution of the average Target Price on Neumora Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b5a05e3d047a4484e41.MjZCNZN2SsQfOFvTuC6gblnUFr7AG3laVkVeHciZZvQ.SAY1GKUaLKtMWziB6RfXKzOnZcaPTi4tERYqW7DvBbJeA3FUyz8GoXALOA~c30310e53ab00b88a37b41dc1498b254

Analyst Recommendations on Neumora Therapeutics, Inc.

JPMorgan Adjusts Price Target on Neumora Therapeutics to $22 From $20, Maintains Overweight Rating	Mar. 18	MT
RBC Raises Price Target on Neumora Therapeutics to $31 From $24, Keeps Outperform, Speculative Risk	Mar. 08	MT
Deutsche Bank Initiates Coverage on Neumora Therapeutics With Hold Rating, $13 Price Target	Dec. 12	MT
JPMorgan Initiates Neumora Therapeutics at Overweight Rating With $21 Price Target	23-10-10	MT
BofA Securities Initiates Neumora Therapeutics at Buy Rating	23-10-10	MT
RBC Initiates Neumora Therapeutics at Outperform, Speculative Risk With $24 Price Target Amid Bullish View on Lead Drug in Major Depressive Disorder	23-10-10	MT
Guggenheim Starts Neumora Therapeutics at Buy With $22 Price Target	23-10-10	MT
William Blair Starts Neumora Therapeutics With Outperform Rating	23-10-10	MT
BofA Securities Starts Neumora Therapeutics With Buy Rating	23-10-10	MT
Stifel Starts Neumora Therapeutics at Buy	23-10-10	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.58 USD

Average target price

24.51 USD

Spread / Average Target

+155.83%

High Price Target

29 USD

Spread / Highest target

+202.71%

Low Price Target

22 USD

Spread / Lowest Target

+129.65%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Neumora Therapeutics, Inc.

JPMorgan Chase
RBC Capital Markets
Deutsche Bank Securities
BofA Securities
Guggenheim
Stifel Nicolaus
William Blair & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar